. 2008 May 12;94(12):1548–1558. doi: 10.1136/hrt.2008.141648

Table 1. Characteristics of randomised trials comparing early versus late Gp IIb–IIIa inhibitor administration in primary angioplasty.

Study	Period	Study design (no of patients)	Symptom duration, hours	Stent	Primary endpoints	Follow-up duration
ReoPro-BRIDGING¹³	2003–4	Early (n = 28) versus late (n = 27) abciximab*	<6	Yes	Preprocedural TIMI 3 flow, cTFC and MACE	1 year
RELAx-AMI¹⁴	2003–4	Early (n = 105) versus late (n = 105) abciximab*	<6	Yes	Preprocedural TIMI 3 flow, ST resolution, myocardial salvage	30 days
Rakowski et al¹⁵	2004	Early (n = 25) versus late (n = 30) abciximab*	<12	Yes	Preprocedural TIMI 3 flow, ST resolution, LVF	1 year
ERAMI¹⁶	2001–2	Early (n = 36) versus late (n = 38) abciximab)*	<12	nr	Preprocedural TIMI flow	1 year
Zorman et al¹⁷	1998–2001	Early (n = 56) versus late (n = 56) abciximab*	<12	Yes	Early (60 minutes) ST-segment resolution, preprocedural 3 TIMI flow	6 months
REOMOBILE¹⁸	2001–2	Early (n = 52) versus late (n = 48) abciximab*	<6	Yes	Preprocedural TIMI flow	1 year
Cutlip et al¹⁹	2001–2	Early (n = 28) versus late or no (n = 30) tirofiban†	<12	Yes	Preprocedural TIMI flow	30 days
On-TIME²⁰	2001–2	Early (n = 251) versus late (n = 256) tirofiban†	<6	Yes	Preprocedural TIMI flow	1 year
Emre et al²¹	2002–3	Early (n = 32) versus late (n = 34) tirofiban†	<6	Yes	Myocardial perfusion and functional recovery at 30 days	30 days
INTAMI²²	2002–4	Early (n = 53) versus late or no (n = 49) eptifibatide‡	<12	Yes	Preprocedural TIMI 3 flow	1 year
TITAN-TIMI 34²³	2004–5	Early (n = 180) versus late or no (n = 163) eptifibatide‡	<6	Yes	Preprocedural TIMI frame count	30 days

*0.25 mg/kg intravenous bolus, followed by 0.125 μg/kg per minute infusion (12 h).

†10 μg/kg intravenous bolus followed by 0.15 μg/kg per minute infusion (24 h).

‡180 μg/kg intravenous double bolus followed by 2.0 μg/kg per minute infusion (12–24 h).

cTFC, corrected TIMI frame count; Gp, glycoprotein; LVF, left ventricular function; MACE, major adverse cardiac events; nr, not reported; TIMI 3, Thrombolysis in Myocardial Infarction Study grade 3 flow.